given as a subcutaneous injection. Dupixent is a biologic and belongs to a drug class called interleukin-4 (IL-4) receptor blockers. The medication is not available in a biosimilar version.

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

This includes medicated creams and pills, dupilumab (Dupixent ... not improved with topical drugs. If people have Original Medicare, Part B covers phototherapy and injection treatments for ...

The IL-4 and IL-13 targeting antibody is administered as a subcutaneous injection ... of Dupixent, having begun the process in August. Based on previous timelines for similar drugs, Sanofi may ...

Novartis has axed development of its mid-stage eczema drug ZPL389 ... towards an important FDA approval for its Dupixent (dupilumab) injection for the skin disease also known as atopic dermatitis.

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other ...